X-Chem Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States.
ACS Chem Biol. 2024 Apr 19;19(4):802-808. doi: 10.1021/acschembio.3c00803. Epub 2024 Mar 25.
The identification of novel covalent ligands for therapeutic purposes has long depended on serendipity, with dedicated hit finding techniques emerging only in the early 2000s. Advances in chemoproteomics have enabled robust characterization of putative drugs to derisk the unique liabilities associated with covalent hit molecules, leading to a renewed interest in this targeting modality. DNA-encoded library (DEL) technology has similarly emerged over the past two decades as a highly efficient method to identify new chemical equity toward protein targets of interest. A number of commercial and academic groups have reported methods in covalent DEL synthesis and hit identification; however, it is evident that there is still much to be done to fully realize the power of this technology for covalent ligand discovery. This perspective will explore the current approaches in covalent DEL technology and reflect on the next steps to advance this field.
新型共价配体的鉴定长期以来一直依赖于偶然发现,专门的命中发现技术直到 21 世纪初才出现。化学生物组学的进步使人们能够对假定的药物进行强有力的表征,以降低与共价命中分子相关的独特风险,从而重新引起人们对这种靶向模式的兴趣。DNA 编码文库 (DEL) 技术在过去二十年中也作为一种高效的方法出现,用于鉴定对感兴趣的蛋白质靶标的新化学物质。许多商业和学术团体已经报道了共价 DEL 合成和命中鉴定的方法;然而,显然还有很多工作要做,才能充分发挥该技术在共价配体发现方面的威力。本文将探讨共价 DEL 技术的当前方法,并思考推进该领域的下一步措施。